TNFRSF8 and mycosis fungoides: BV has been indicated for the treatment of adult patients with relapsed classic Hodgkin lymphoma (cHL), systemic anaplastic large-cell lymphoma (sALCL), primary cutaneous anaplastic large-cell lymphoma (pcALCL), or CD30 expressing mycosis fungoides (MF) [16].